Immunotherapy in non-small cell lung cancer: current status, advances and challenges

被引：0
|
作者：
Tartarone, Alfredo [1 ]
Lerose, Rosa [2 ]
Tartarone, Marina [3 ]
机构：
[1] IRCCS CROB Referral Canc Ctr Basilicata, Dept Onco Hematol, Div Med Oncol, Via Padre Pio 1, I-85028 Rionero In Vulture, Potenza, Italy
[2] IRCCS CROB Referral Canc Ctr Basilicata, Hosp Pharm, Rionero In Vulture, Potenza, Italy
[3] Humanitas Univ, Milan, Italy
来源：
MINERVA RESPIRATORY MEDICINE | 2024年 / 63卷 / 03期
关键词：
Carcinoma; non-small-cell lung; Immunotherapy; Immune checkpoint inhibitors; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; 1ST-LINE TREATMENT; BRAIN METASTASES; POOLED ANALYSIS; CHECKMATE; 9LA; PEMBROLIZUMAB; CHEMOTHERAPY; DOCETAXEL; PHASE-3;
D O I：
10.23736/S2784-8477.24.02108-9
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
In recent years, thanks to the advent of immunotherapy, the therapeutic landscape of non-oncogene-addicted non-small cell lung cancer (NSCLC) has undergone a complete revolution. So far, several monoclonal antibodies directed against PD-1, PD-L1, or CTLA-4, known as immune checkpoint inhibitors (ICIs), administered alone or in combination with other agents have shown efficacy in metastatic setting as well as, more recently, even in the early-stage. We reviewed the role of immunotherapy in NSCLC focusing the attention not only on the results of the main currently available clinical trials but also on novel combination strategies.
引用
下载
收藏
页码：110 / 120
页数：11
相关论文
共 50 条
  • [31] Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives
    Andrea Ciarmiello
    Rosa Fonti
    Giampiero Giovacchini
    Silvana Del Vecchio
    Clinical and Translational Imaging, 2018, 6 : 483 - 485
  • [32] New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer
    Luna, Javier
    Zafra, Juan
    Areses Manrique, Ma Carmen
    Rodriguez, Aurora
    Sotoca, Amalia
    Firvida, Jose Luis
    Chicas-Sett, Rodolfo
    Mielgo, Xabier
    Reyes, Juan Carlos Trujillo
    Counago, Felipe
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 983 - 999
  • [33] Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives
    Ciarmiello, Andrea
    Fonti, Rosa
    Giovacchini, Giampiero
    Del Vecchio, Silvana
    CLINICAL AND TRANSLATIONAL IMAGING, 2018, 6 (06) : 483 - 485
  • [34] Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges
    Li Chu-Ling
    Song Yong
    中华医学杂志(英文版), 2021, 134 (16) : 1908 - 1919
  • [35] Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges
    Li, Chu-Ling
    Song, Yong
    CHINESE MEDICAL JOURNAL, 2021, 134 (16) : 1908 - 1919
  • [36] CURRENT STATUS OF CHEMOTHERAPY FOR NON-SMALL CELL LUNG-CANCER
    AISNER, J
    HANSEN, HH
    CANCER TREATMENT REPORTS, 1981, 65 (11-1): : 979 - 986
  • [37] CURRENT STATUS OF TARGETED THERAPY IN NON-SMALL CELL LUNG CANCER
    Parums, D. V.
    DRUGS OF TODAY, 2014, 50 (07) : 503 - 525
  • [38] The current status of targeted therapy for non-small cell lung cancer
    Francis, H.
    Solomon, B.
    INTERNAL MEDICINE JOURNAL, 2010, 40 (09) : 611 - 618
  • [39] The current status of docetaxel for advanced non-small cell lung cancer
    Green, MR
    ANTI-CANCER DRUGS, 2001, 12 : S11 - S16
  • [40] Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
    Mayor, Marissa
    Yang, Neng
    Sterman, Daniel
    Jones, David R.
    Adusumilli, Prasad S.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 49 (05) : 1324 - 1333
12345